EU CanScreen
European Joint Action on Cancer Screening

EUCanScreen – Expected Results & Impact

Implementation of cancer screening programmes

Mārcis LEJA
Ilze KAUPE
University of Latvia

Rome
28 October, 2026
Joint Stakeholder Conference

Co-funded by the European Union

EUCanScreen at a Glance

Total project budget: € 38,749,935


EC contribution 80%: € 30,999,929

Duration: June 2024 – May 2028

Project Lead: University of Latvia

Partnership 97: 29 beneficiaries, 61 affiliated entities and 7 associated partners.

71 public bodies, 13 universities,
13 hospitals.



Objective



EUCanScreen aims to ensure the sustainable implementation of high-quality screening programmes for breast, cervical, and colorectal cancers, along with the integration of newly recommended screening programmes for lung, prostate, and gastric cancers.


The project is focused on reducing the overall cancer **burden** and promoting **equity** in cancer care across the EU.

Project Vision, Mission, Goals

EU CanScreen
European Joint Action on Cancer Screening




Work packages



Expected Impact and Benefits

EU CanScreen
European Joint Action on Cancer Screening



Lower Cancer Rates
Incidence and mortality reductions.

Better Quality of Life
Early detection saves lives and health.

Healthcare Efficiency
Optimised resource use and cost savings.

Screening Equity
Equal access to life-saving tests.

Stronger Collaboration
EU-wide cancer control partnerships.

Expected Results and Benefits to the Patients and Society

EU CanScreen
European Joint Action on Cancer Screening

- Early detection and cancer mortality reduction: Improved cancer survival rates through facilitation of high-quality screening, detecting cancers at earlier, curable stages.
- Enhanced screening programmes: Strengthening national screening programmes via cross-border expertise and evidence-based decision-making.
- Personalised screening: Integration of AI and risk-based methods for more targeted, effective, and less invasive screenings.
- Training and expertise: Establishment of regional centres and specialised training to improve screening quality across Europe.
- Wider societal impact: Increased awareness and participation in screenings, leading to better health outcomes and reduced cancer burden.
- Cost-effectiveness: Tools for cost analysis to optimise resource use and ensure long-term sustainability of screening programmes.

Key outputs and Expected long-term impact

Guidelines and Toolkits with practical tools

Data solutions, evidence from pilot studies and modelling

Trained professionals

Higher-quality, more accessible cancer screening

Earlier cancer detection

Reduced cancer mortality

Stronger collaboration with

Key achievements in 28 months (1)

- **Established two regional training centres:** an LDCT lung cancer screening centre in Budapest with 10 equipped workstations, and a mammography training centre in Riga, with initial courses scheduled for November 2026.
- **Delivered practical specialist training:** 94 graduates from nine LDCT courses, 15 participants in two accredited colonoscopy trainer courses, and 44 participants in a completed colposcopy training programme.
- **Expanded access to accredited online training:** the LDCT course attracted 389 registrations from 70 countries, with 68 completions recorded by August 2026.

Key achievements in 28 months (2)

- **Developed the EUCanSTREAM barrier assessment tool and user guidance:** tested the tool's concept in a workshop to support systematic assessment of barriers to cancer screening.
- **Country-to-country support into practice:** held the first targeted support visit to Estonia, bringing together experts from Denmark, Slovenia and Sweden to address screening governance and sustainability.
- **Identified implementation barriers for digital decision aids:** gathered evidence from 34 screening professionals across 16 EU countries, highlighting integration into existing screening pathways as a key support need.

Key achievements in 28 months (3)

- **Produced preliminary modelling results:** calculated cervical screening scenarios for HPV-vaccinated populations and initial estimates of net benefit and return on investment to inform screening prioritisation.
- **Completed a systematic review and mapping of economic evaluations of multicancer early detection tests**, providing an evidence base for further assessment.

Partnership & Collaboration

EU CanScreen
European Joint Action on Cancer Screening

National Agencies

Engagement with leading cancer organisations.

Stakeholder Involvement

Includes policymakers, healthcare workers.

Strong Networks

European Cancer Screening Network formation.

Key Collaborators

Partnerships with European Commission and WHO Europe.



EU CanScreen
European Joint Action on Cancer Screening

Thank you!

screening@lu.lv

Co-funded by
the European Union

Disclaimer
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.